Zai Lab And Argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China
Zai Lab And Argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China
再鼎醫藥與Argenx獲批在中國推出用於全身性重症肌無力的Efgartigimod alfa皮下注射劑
- First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China
- Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study
- 作爲中國唯一獲得國家藥監局批准的皮下注射劑，爲重症肌無力患者提供額外的靈活性和選擇性。
- 第三階段ADAPt-SC研究表明，與靜脈注射相比，efgartigimod SC具有一致的臨床效益和安全性。